Skip to content

Med-stat.info

The latest health news

  • Coronavirus
  • Biotech
  • Health Tech
  • First Opinion
  • In the Lab
  • Pharma
Main Menu

Tag: Biosimilars

First Opinion

Opinion: To protect the medical supply chain, ‘made in America’ will be key

14.12.2022

The Covid-19 pandemic exposed a serious flaw in the United States’ medical supply chain: an overreliance on imported supplies. Reinvigorating a domestic supply chain is an important step toward protecting …

Read More
Pharma

Virtual Event: Biosimilars’ Meteoric Moment

12.10.2022

Editor’s note: A livestream of the event is embedded below. Like approaching asteroids, major biosimilars for Humira and other drugs are finally due to hit the market in 2023. Should …

Read More
First Opinion / Pharma

Opinion: Market share isn’t the only metric for biosimilars’ success

23.09.2022

Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of …

Read More
First Opinion

Opinion: Biosimilars competition helps patients more than generic competition

08.10.2021

Much of the current drug-pricing agenda proposed by President Biden and by Congress is based on the belief that greater government control — rather than free market competition — is …

Read More
First Opinion

Opinion: FDA’s naming rule for biosimilars has undermined Congress and health care

04.10.2021

I recently tried to order white blood cell growth factor (pegfilgrastim) biosimilar for one of my patients. This is a drug that helps prevent fever and infection associated with low …

Read More
Health

Virtual Event: The evolving landscape for biosimilars

30.09.2021

Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. Biosimilars were anticipated to be a solution to the soaring cost of prescription medicines to …

Read More
Health

Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch

21.09.2021

It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain and digestion problems, fatigue and hot, red rashes. But even after learning in 2016 …

Read More
First Opinion

Opinion: The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means

29.07.2021

The Food and Drug Administration’s decision on Wednesday to approve a long-acting insulin called Semglee (insulin glargine-yfgn) as the first interchangeable biologic licensed for the U.S. market represents a major …

Read More
Copyright © Med-stat.info
  • Terms of Service
  • Privacy Policy